Ropinirole in the Treatment of Patients With Restless Legs Syndrome: A US-Based Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Bogan, Richard; Fry, June M.; Schmidt, Markus H.; Carson, Stanley W.; Ritchie, Sally Y.

doi:10.4065/81.1.17

Cited by 138 publications

(63 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1617181920212223242526] Some of these studies have included cases which were older in age as compared to the cases included in the present study. [202526] The methodology of the studies conducted in past some of them was open label,[23] some randomized,[171920212526] and few were single blind,[22] while others were double blinded. [1920212526] Some had placebo control,[17181920212526] while others were cross-over trials.…”

Section: Discussionmentioning

confidence: 99%

“…[202526] The methodology of the studies conducted in past some of them was open label,[23] some randomized,[171920212526] and few were single blind,[22] while others were double blinded. [1920212526] Some had placebo control,[17181920212526] while others were cross-over trials. [18] Having trials with diverse methodologies make the comparison difficult.…”

Section: Discussionmentioning

confidence: 99%

“…As far as the dose of ropinirole is concerned, most of them had prescribed ropinirole in the dose range of 0.25–4 mg/day[1719212526] except one where doses as high as 6 mg/day were prescribed. [18] All the studies have found that ropinirole was well tolerated with minimal and mild adverse effects[1718192021222326] and in one study treatment, discontinuation was seen in only 9% due to adverse effects. [23] These studies have reported that adverse effects were dose related, and hence the lower incidence of adverse effects in the present study could be related to low dosage.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A double-blind, randomized, controlled trial to compare the efficacy and tolerability of fixed doses of ropinirole, bupropion, and iron in treatment of restless legs syndrome (Willis-Ekbom disease)

Vishwakarma

Kalra

Gupta

et al. 2016

Ann Indian Acad Neurol

View full text Add to dashboard Cite

Background:We aimed to compare the efficacy of fixed doses of bupropion and ropinirole and iron alone for the treatment of restless legs syndrome (RLS) and to look for the tolerability of these medications.Materials and Methods:Patients diagnosed with RLS were randomly divided into three groups with thirty patients in each group (Group A: Bupropion [300 mg/day], Group B: Ropinirole [0.25–0.5 mg/day], and Group C: Oral iron [150 mg elemental iron] along with folic acid [500 μg]). Each participant was then assessed for severity of RLS, as well as RLS-related quality at the baseline, and thereafter, every 14th day till 6 weeks based on the International Restless Legs Scale (IRLS) severity rating scale and Restless Legs Syndrome Quality of Life (RLSQoL) Questionnaire, respectively.Results:IRLS scores differed significantly from baseline visit to last (F = 4.85; P = 0.01). The interaction between the time x treatment group was significant (F = 10.37; P < 0.001) showing an improvement with the therapy in all the groups. Pair-wise comparison depicted that ropinirole group differed from other two groups in IRLS score (F = 7.06; P = 0.001), which were comparable to each other. Regarding quality of life of these cases, within each group scores differed among all the four visits (F = 5.12; P = 0.002). Unlike IRLS, there was no significant difference among the RLSQOL scores between groups at any point of time (F = 1.2; P = 0.28).Conclusion:RLS severity decreased across time in all three groups; however, the ropinirole treatment was better than the bupropion and iron-folate therapy. Moreover, RLS-related quality of life although improved among all groups, it was comparable among three groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A double-blind, randomized, controlled trial to compare the efficacy and tolerability of fixed doses of ropinirole, bupropion, and iron in treatment of restless legs syndrome (Willis-Ekbom disease)

Vishwakarma

Kalra

Gupta

et al. 2016

Ann Indian Acad Neurol

View full text Add to dashboard Cite

show abstract

“…: +86 13772187729; fax: +86 29 84773636. therapy for idiopathic PD. In addition to PD, ropinirole has also been used successfully in the treatment of restless legs syndrome [2] and psychosis [3]. Ropinirole and levodopa are both inactivated by liver metabolism.…”

Section: Introductionmentioning

confidence: 99%

The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers

Wen

Jia

Luo

et al. 2007

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

“…Dopaminergic agonists are the first-line agents for the treatment of RLS symptoms [14]. Several randomized controlled studies showed significant changes if patients were treated with 0.25-6 mg/day of ropinirole for 4-12 weeks (table 4) [38,39,40]. The efficacy of ergot agonists such as cabergoline (2 mg) was demonstrated in studies employing levodopa as the active comparator [41].…”

Section: The Place Of Rotigotine In the Treatment Of Rlsmentioning

confidence: 99%

Rotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome

et al. 2014

View full text Add to dashboard Cite

Rotigotine, a nonergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMA and FDA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease or with moderate-to-severe restless legs syndrome (RLS). This review comprises an overview of the pharmacokinetics, the pharmacodynamics and the clinical efficacy and safety of the rotigotine transdermal patch for RLS. Its source material was identified by a PubMed search for the terms ‘rotigotine' and ‘RLS'. The rotigotine transdermal patch demonstrates clinical efficacy alongside a good tolerability profile. Application site reactions were the most frequent adverse events, and they were considered mild to moderate in the majority of cases. In summary, the rotigotine transdermal patch offers a safe and efficacious alternative for the treatment of RLS. Further studies should focus on the possibility that continuous dopamine stimulation by means of transdermal patches might have an influence on RLS augmentation rates.

show abstract

Ropinirole in the Treatment of Patients With Restless Legs Syndrome: A US-Based Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Cited by 138 publications

References 33 publications

A double-blind, randomized, controlled trial to compare the efficacy and tolerability of fixed doses of ropinirole, bupropion, and iron in treatment of restless legs syndrome (Willis-Ekbom disease)

A double-blind, randomized, controlled trial to compare the efficacy and tolerability of fixed doses of ropinirole, bupropion, and iron in treatment of restless legs syndrome (Willis-Ekbom disease)

The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers

Rotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome

Contact Info

Product

Resources

About